Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Individualizing therapy for early, middle-of-the-night and late-night insomnia.

M B Scharf1

  • 1Center for Research in Sleep Disorders, Cincinnati, Ohio, USA.

International Journal of Clinical Practice. Supplement
|February 24, 2001
PubMed
Summary

New sleep medication Zaleplon offers a flexible treatment for insomnia, addressing nighttime awakenings without causing next-day impairment. This non-benzodiazepine provides a safe option for managing sleep difficulties effectively.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcome evaluation of long-term nasal continuous positive airway pressure therapy in obstructive sleep apnea.

American journal of therapeutics·2001
Same author

Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia.

Clinical neuropharmacology·2000
Same author

Zolpidem for persistent insomnia in SSRI-treated depressed patients.

The Journal of clinical psychiatry·1999
Same author

Evaluation of sleep architecture and cyclic alternating pattern rates in depressed insomniac patients treated with nefazodone hydrochloride.

American journal of therapeutics·1999
Same author

Diagnostic and treatment implications of nasal obstruction in snoring and obstructive sleep apnea.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·1998
Same author

Effect of gamma-hydroxybutyrate on pain, fatigue, and the alpha sleep anomaly in patients with fibromyalgia. Preliminary report.

The Journal of rheumatology·1998

Area of Science:

  • Pharmacology
  • Sleep Medicine
  • Neurology

Background:

  • Insomnia frequently involves difficulty maintaining sleep, leading to daytime fatigue and functional impairment.
  • Current treatments, often administered at bedtime, may not suit all insomnia patients.
  • Effective insomnia management requires addressing underlying causes and specific sleep complaints.

Purpose of the Study:

  • To introduce Zaleplon as a novel therapeutic agent for insomnia.
  • To evaluate Zaleplon's suitability for flexible administration during the night.
  • To assess Zaleplon's safety and efficacy in managing insomnia without next-day side effects.

Main Methods:

  • Zaleplon, a non-benzodiazepine hypnotic, was investigated for its pharmacokinetic profile.
  • The study focused on Zaleplon's rapid absorption and elimination characteristics.

Related Experiment Videos

  • Assessment of potential next-day psychomotor and cognitive impairment was a key aspect.

    • Main Results:

    • Zaleplon demonstrates rapid absorption and elimination, enabling timely administration.
    • Its use allows for treatment at bedtime or later in the night.
    • Significant next-day impairment of psychomotor and cognitive functioning was not observed.

    Conclusions:

    • Zaleplon is an effective and safe pharmacotherapeutic option for insomnia.
    • Its pharmacokinetic profile supports flexible dosing for managing sleep maintenance issues.
    • Zaleplon offers a valuable alternative for patients needing to manage nighttime awakenings without residual effects.